title: Cancer subclonal genetic architecture as a key to personalized medicine.
abstract: The future of personalized oncological therapy will likely rely on evidence-based medicine to integrate all of the available evidence to delineate the most efficacious treatment option for the patient. To undertake evidence-based medicine through use of targeted therapy regimens, identification of the specific underlying causative mutation(s) driving growth and progression of a patient's tumor is imperative. Although molecular subtyping is important for planning and treatment, intraclonal genetic diversity has been recently highlighted as having significant implications for biopsy-based prognosis. Overall, delineation of the clonal architecture of a patient's cancer and how this will impact on the selection of the most efficacious therapy remain a topic of intense interest.
authors.affiliation: Departments of Radiation Oncology and Radiology, University of Michigan, Ann Arbor, MI.
authors.forename: Alnawaz
authors.initials: A
authors.lastname: Rehemtulla
mesh_terms: D019317:Evidence-Based Medicine; D006801:Humans; D025202:Molecular Diagnostic Techniques; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D057285:Precision Medicine / Q000639:trends*